EyePoint ($EYPT) Insider Trading & Smart Money Activity

EyePoint, Inc. · Biotechnology · Latest filing Jul 1, 2026

EyePoint, Inc. ($EYPT) has 2 13F position changes and 2 analyst ratings on file.

Insider buyers (12 mo)

0

Insider sellers (12 mo)

0

Net insider $ (12 mo)

$0

Congress trades (12 mo)

0

13F moves on file

2

Analyst ratings on file

2

EYPT insider buying and selling by quarter

Quarter	Insider buys	Insider sales	Congress buys / sales	13F added / cut
Q1 2026	0	0	0 / 0	0 / 0
Q2 2026	0	0	0 / 0	0 / 2
Q3 2026	0	0	0 / 0	0 / 0
Q4 2026	0	0	0 / 0	0 / 0

Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.

All EYPT insider, congress, 13F and analyst activity

All 13F Analysts

Date	Source	Who	Action	Shares	Value / amount	ΔOwn	1W	1M	6M	Filing	Story
Jul 1, 2026	Analyst	Chardan Capital	Reiterates to buy		PT $65		+6.1%	-7.2%			Read
Jun 24, 2026	Analyst	Guggenheim	Reiterates to buy		PT $68		-8.3%	-15.3%			Read
May 7, 2026	13F	Dekabank Deutsche Girozentrale	Sold out	-35K sh			-1.3%	-14.6%			—
May 7, 2026	13F	Dekabank Deutsche Girozentrale	Sold out	-35K sh			-1.3%	-14.6%			—

1W / 1M / 6M = how EYPT moved from the trade or filing date.

Institutions moving EYPT (13F)

• Dekabank Deutsche Girozentrale2

Analyst ratings on EYPT

Date	Firm	Action	Rating	Price target	1W	1M	6M	Story
Jul 1, 2026	Chardan Capital	Reiterates	buy	$65	+6.1%	-7.2%		Read
Jun 24, 2026	Guggenheim	Reiterates	buy	$68	-8.3%	-15.3%		Read

Frequently asked questions

Which institutions changed their EYPT positions?

Recent 13F filers moving the stock include Dekabank Deutsche Girozentrale.

Other biotechnology stocks

• $EVMN
• $LXEO
• $IPSC
• $PROK
• $CMPX
• $ABEO
• $BBOT
• $OBIO

Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.